Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$268.00 | Swxf | Fdwmkkcgl |
Eli Lilly: Positive Tirzepatide Data in Obstructive Sleep Apnea Reinforces Drug's Massive Potential
We are holding our fair value estimate for Eli Lilly steady after the company reported positive tirzepatide (Mounjaro/Zepbound) data in treating obstructive sleep apnea and obesity. We had largely expected the positive results, which support our robust peak annual sales forecast for the drug at over $60 billion annually across all indications. The solid data does help reinforce the company’s wide moat.